Therapy of experimental Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin.
D036002:ADP Ribose Transferases; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001427:Bacterial Toxins; D002056:Burns / Q000150:complications*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005098:Exotoxins / Q000276:immunology / Q000633:toxicity; D005260:Female; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology; D037521:Virulence Factors; D014946:Wound Infection / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D002939:Ciprofloxacin; D005098:Exotoxins; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A